Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors

Medicine & Life Sciences

1. B-Lymphocyte Epitopes 100%
2. Vaccines 53%
3. Neoplasms 33%
4. Immune System 26%
5. Combined Vaccines 22%
6. Subunit Vaccines 20%
7. Trastuzumab 19%
8. ErbB Receptors 16%
9. Antibodies 13%
10. Immunologic Memory 11%
11. Active Immunotherapy 10%
12. Clinical Trials 10%
13. Immunologic Monitoring 10%
14. Uterine Neoplasms 10%
15. Peptides 10%
16. Passive Immunization 10%
17. Ergonomics 10%
18. Neoplasm Antigens 8%
19. Humoral Immunity 8%
20. Endometrial Neoplasms 8%
21. Esophageal Neoplasms 8%
22. Cellular Immunity 8%
23. Ovarian Neoplasms 7%
24. In Vitro Techniques 7%
25. Stomach Neoplasms 7%
26. Immunization 7%
27. Vaccination 6%
28. Lung Neoplasms 6%
29. Patient Care 6%
30. Poisons 6%
31. Public Health 5%
32. Clinical Studies 5%
33. Breast Neoplasms 5%
34. Physicians 5%
35. T-Lymphocytes 5%
36. Neoplasm Metastasis 5%